Human Genome Sciences announced Thursday it had rejected an unsolicited offer of his longtime partner GlaxoSmithKline that values around 2.6 billion (2 billion).
GSK's offer, to 13 dollars per share, represents a premium of 81% over the closing price of 7.17 dollars for action Human Genome Wednesday night, but the U.S. group believes it does not reflect its intrinsic value.
In pre-market Human Genome soared over 100% to trade at just over $ 15, a sign that the market is betting on a bidding war in this new battle that promises to within a pharmaceutical industry recently marked by a wave of consolidation.
Human Genome, American laboratory that specializes in gene isolation and identification of their function in the development of new drugs, said banks have mandated Goldman Sachs and Cre Swiss said the counselor.
First British pharmaceutical company, GSK said he was disappointed in a statement of rejection of his offer without discussion. The group confirmed its offer, stating that the proposed price of $ 13 would be paid in cash.
He also said to expect the transaction provides for the realization by 2015 at least $ 200 million of cost synergies, and that it will be accretive to from 2013.
If GSK has been a tendency in the past not to buy out partners with whom he works, the rumor of an offer to GSK on its U.S. partner ran long, the two companies already collaborate ; over several treatments, including Benlysta, the first new drug against lupus in more than half a century.
Navid Malik, analyst at Cenkos Securities, indicates that GSK extremely knowledgeable Human Genome and must point to a potential value in excess of one Benlysta.
Both groups are also working on a project called darapladib treatment of heart, now in the third and final phase of experimental tests.
If product development is going to an end, analysts see it as a "blockbuster" possible multi-billion dollar per year, although the molecule is also accompanied by a high level of risks.
A banker in the health sector considers the offer of generous and GSK believes that certain shareholders of Human Genome could accept it.
Others, however, prefer to wait an increase of the price. They know the appetite of big pharmaceutical companies for biotech in their search for new growth after the expiration of patents on several of their blockbuster drugs.
As recently as Wednesday, the American Illumina rejected a hostile bid of 6.8 billion dollars (5.2 billion euros) of the Swiss laboratory Roche Holding.